Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study

Pharmacogenomics. 2018 Oct;19(15):1169-1179. doi: 10.2217/pgs-2018-0088. Epub 2018 Sep 12.


Aim: To compare pharmacogenetic test predictions with self-reported treatment experience and side effect tolerability among patients with depression taking psychotherapeutic medications.

Methods: Subjects completed a survey recalling medication effectiveness and side effects and then underwent pharmacogenetic testing.

Results: Our 15 gene pharmacogenetic panel predicted efficacy (p < 0.001) but did not predict side effect tolerability (p = 0.70) in a group of 352 patients. The pharmacogenetic panel and reported efficacy corresponded 60% of the time and medication tolerability agreed 71% of the time.

Conclusion: Pharmacogenetic testing may be a useful adjunct to predict efficacy of medications used to treat depression.

Keywords: antidepressant; antipsychotic; bipolar disorder; generalized anxiety disorder; major depressive disorder; mood stabilizer; pharmacogenetics; selective serotonin reuptake inhibitors; tricyclic antidepressants.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antidepressive Agents, Tricyclic / therapeutic use*
  • Bipolar Disorder / drug therapy*
  • Bipolar Disorder / genetics*
  • Cross-Sectional Studies
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / genetics*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pharmacogenetics / methods
  • Pharmacogenomic Testing / methods
  • Psychotropic Drugs / therapeutic use*
  • Retrospective Studies
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Young Adult


  • Antidepressive Agents, Tricyclic
  • Psychotropic Drugs
  • Serotonin Uptake Inhibitors